AI Workflow for Gene and Cell Therapy CMC Module Assembly and Comparability Analysis

The CMC module for advanced therapies is a high-stakes compilation of manufacturing process descriptions, analytical characterization, and comparability studies, typically assembled manually from fragmented LIMS, ELN, and QMS systems. This manual process creates a 6-12 week bottleneck, delaying submissions and increasing the risk of data inconsistencies that trigger major regulatory questions. A custom automation workflow orchestrates agents to extract, validate, and structure this data into draft Module 3 narratives, cutting compilation time by over 70% and ensuring traceability from source systems to submission-ready content.

Implementation integrates with Veeva Vault, Documentum, or similar RIM systems, using LangGraph to coordinate extraction agents, validation logic against ICH guidelines, and structured narrative assembly. The workflow includes mandatory human review gates for process changes and analytical method justifications, with full audit trails for data lineage. This architecture transforms CMC from a manual, error-prone compilation into a repeatable, governed process that accelerates time-to-submission while strengthening data integrity for agency scrutiny.

This workflow automates the extraction, structuring, and narrative assembly of CMC data from fragmented sources like LIMS (e.g., LabVantage), ERP (e.g., SAP), and electronic lab notebooks. Specialized agents retrieve raw process descriptions, analytical results, and stability data, then draft the required technical narratives for Module 3. The operational upside comes from reducing a manual, expert-driven process from months to days, cutting submission preparation time by over 60% and minimizing the risk of data transcription errors that trigger regulatory questions.

Implementation requires orchestrating these agents—using a framework like LangGraph—with strict governance. Each agent's output routes through a validation layer that checks against ICH guidelines and internal templates. Exceptions or low-confidence data are flagged for human review within systems like Veeva Vault RIM. The final architecture integrates with submission publishing tools, ensuring the assembled CMC module is technically valid, traceable back to source systems, and ready for inclusion in the final eCTD sequence.

Begin with a targeted pilot automating the compilation of analytical characterization data from a single source, such as a LIMS like Thermo Fisher SampleManager. This first phase focuses on a high-volume, repetitive task to demonstrate immediate time savings for scientists and establish trust in the agentic workflow. The architecture uses a lightweight orchestrator, like a custom LangGraph application, to extract, validate, and format data into predefined Module 3 templates, with all outputs routed through a human-in-the-loop review checkpoint in Veeva Vault.

Subsequent phases expand the orchestration layer to integrate manufacturing process descriptions from MES (e.g., PAS-X) and comparability study results from statistical platforms (e.g., JMP). Each phase adds a new agent or data source, governed by the same review and approval gates. This iterative approach allows for continuous validation of data quality and narrative coherence, ultimately building towards a full Module 3 assembly workflow that connects to the Regulatory Information Management (RIM) system for final submission packaging and tracking.

A production-grade CMC workflow requires embedded governance to ensure data integrity and auditability. The architecture must enforce role-based access controls, maintain a complete, immutable audit trail of all agent actions and data transformations, and implement electronic signatures for critical approval gates. This is non-negotiable for FDA/EMA scrutiny. Controls are designed at the data-ingestion layer (validating source data from LIMS, ERP, and ELN systems), the orchestration layer (logging agent decisions), and the output layer (locking finalized documents). The system must produce defensible evidence of ALCOA+ principles for every data point in the final submission.

Phased rollout is critical to manage operational risk. Phase 1 targets a single, well-defined comparability study, automating data extraction and table generation while keeping narrative drafting in a human-in-the-loop review mode. Phase 2 expands to full process description assembly across multiple drug substance and drug product stages, integrating more source systems. Phase 3 deploys the full multi-agent orchestration for end-to-end Module 3 compilation. Each phase includes parallel runs against manual processes, with discrepancy analysis and tuning of agent logic. This measured approach builds organizational trust, refines exception handling, and delivers incremental ROI while de-risking the final automated submission.

This workflow automates the high-stakes, manual bottleneck of compiling CMC data from fragmented LIMS, ERP, and quality systems for gene and cell therapy BLAs. It reduces a 6-8 week process to days by orchestrating agents that retrieve manufacturing process descriptions, analytical characterization data, and stability results. The system structures this data into draft Module 3 narratives and tables, directly addressing the critical scrutiny this section receives from regulators, while ensuring traceability and version control across all source documents.

Implementation integrates with systems like Veeva Vault and SAP, using retrieval-augmented generation (RAG) over internal SOPs and ICH guidelines to ensure narrative compliance. The architecture includes mandatory human review gates for scientific and regulatory sign-off, with automated validation checks for data consistency between process descriptions, specifications, and comparability conclusions. This creates a repeatable, audit-ready operating model that cuts preparation time by over 70% and mitigates the risk of major deficiencies in a submission's most scrutinized module.